Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 AhR-mediated serum activities, TCDD equivalents and lipid adjusted POP markers in serum

From: Dioxin-like activities in serum across European and Inuit populations

   Greenland Warsaw Sweden Kharkiv All
AhRag* 1 (RLU/ml serum) N 75 99 78 86 338
  Median 24 34 33 26 29
  Min 6.6 11 8.0 8.8 6.6
  Max 257 118 103 56 257
  % agonist 92 100 95 100 97
AhR-TEQ* 2 (pg/g lipid) N 70 99 76 80 325
  Median 197 312 428 337 310
  Min 38 72 104 110 38
  Max 1188 1054 1261 781 1261
AhRcomp* 3 (RLU/ml serum) N 75 99 78 86 339
  Median 8.3 6.4 6.2 5.5 6.8
  Min 3.9 3.2 1.6 1.5 1.5
  Max 16 9.1 10 11 16
  % add/syn 41 3.0 6.4 18 16
  %antagonist 2.7 8.0 12 34 14
CB-153 (ng/g lipid) N 74 100 98 82 355
  Median 220 16 210 47 78
  Min 5.1 3.3 41 5.5 3.3
  Max 5500 130 1500 200 5500
p,p' -DDE (ng/g lipid) N 74 100 98 82 355
  Median 630 570 240 880 560
  Min 66 240 55 320 55
  Max 13000 2100 2300 12000 13000
  1. *1: AhRag: AhR activity of serum extract alone determined as the relative luciferase activity (RLU) per ml serum; Solvent background control = 6.67 RLU/ml serum. The % agonistic indicates the % of samples eliciting a significant increase in AhR activity compared to the solvent control. *2 AhR-TEQ (TCDD equivalents): The samples eliciting significantly agonistic activity was calculated by interpolation to the TCDD dose-response curve using the Sigmaplot program, given as pg/g serum lipid. *3 AhRcomp: AhR competitive activity of serum extract + 60 pM TCDD (EC50) given as RLU/ml serum. EC50 solvent control = 6.67 RLU/ml serum; % add/syn and %antagonistic indicates the % of samples responding with a further increase or decrease of the EC50(TCDD) induced activity, respectively.